|
Speaker Biographies
Professor Georgina Long AO
Co-Medical Director - Melanoma Institute Australia
Australian of the Year - University of Sydney
Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney.
She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases.
She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.
In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal 2021 and was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016).
She has a number of CINSW Premiers Awards, including; the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow.
Susan Martin
Managing Director - Johnson & Johnson MedTech ANZ
Sue’s career with Johnson & Johnson, the largest healthcare company in the world, spans over 20 years and includes experience across multiple geographies and functions.
Since January 2018, Sue has been Managing Director for Johnson & Johnson MedTech (JJMT) Australia and New Zealand (ANZ). She is responsible for the company’s entire MedTech portfolio in ANZ, including orthopaedics, general and speciality surgery, cardiovascular, and breast reconstructive surgery products, leading a large and dedicated organisation committed to patient care.
Sue is a member and co-chair of the Johnson & Johnson Family of Companies Board in Australia and New Zealand and represents Australia and New Zealand on the MedTech Asia-Pacific Leadership Board.
She is also the executive sponsor for Global Community Impact (GCI) across Johnson & Johnson Australia and New Zealand, which includes overseeing the company’s Reconciliation Action Plan (RAP) in Australia and its Maori Responsiveness Strategy in New Zealand, with a focus on health equity for our First Nations and Maori populations.
Sue has been a board member of the Medical Technology Association of Australia (MTAA) since 2018, and currently serves as Chair of the Board.
|